Hypocretin (orexin) loss in Parkinsons disease

Rolf Fronczek; Sebastiaan Overeem; Sandy Y. Y. Lee; Ingrid. M. Hegeman; Johannes van Pelt; Sjoerd. G. van Duinen; Gert Jan Lammers; Dick F. Swaab
June 2007
Brain: A Journal of Neurology;Jun2007, Vol. 130 Issue 6, p1577
Academic Journal
The hypothalamic hypocretin (orexin) system plays a central role in the regulation of various functions, including sleep/wake regulation and metabolism. There is a growing interest in hypocretin function in Parkinsons disease (PD), given the high prevalence of non-motor symptoms such as sleep disturbances in this disorder. However, studies measuring CSF hypocretin levels have yielded contradictory results. In PD patients and matched controls, we (i) estimated the number of hypocretin neurons in post-mortem hypothalami using immunocytochemistry and an image analysis system (ii) quantified hypocretin levels in post-mortem ventricular CSF and (iii) prefrontal cortex using a radioimmunoassay. Furthermore, presence of Lewy bodies was verified in the hypothalamic hypocretin cell area. Data are presented as median (25th–75th percentile). We showed a significant decrease between PD patients and controls in (i) the number of hypocretin neurons (PD: 20 276 (13 821–31 229); controls: 36 842 (32 546–50 938); P = 0.016); (ii) the hypocretin-1 concentration in post-mortem ventricular CSF (PD: 365.5 pg/ml (328.0–448.3); controls: 483.5 (433.5–512.3); P = 0.012) and (iii) the hypocretin-1 concentrations in prefrontal cortex (PD: 389.6 pg/g (249.2–652.2); controls: 676.6 (467.5–883.9); P = 0.043). Hypocretin neurotransmission is affected in PD. The hypocretin-1 concentration in the prefrontal cortex was almost 40% lower in PD patients, while ventricular CSF levels were almost 25% reduced. The total number of hypocretin neurons was almost half compared to controls.


Related Articles

  • "I'm not lazy I have narcolepsy".  // Filipino Post;3/10/2011, p5 

    The article offers information on narcolepsy, a sleep disorder caused by the inability of the brain to regulate normal cycles of sleep and waking routines and the low regulation of hypocretin brain proteins.

  • Transgenic Sprague Dawley rats with ataxin3-mediated destruction of orexin neurons display reduced tail artery Sympathetic Cutaneous Vasomotor Alerting Responses (SCVARs). Mohammed, M.; Ootsuka, Y.; Yanagisawa, M.; Blessing, B. // Proceedings of the Physiological Society;2013, p293P 

    Orexin neurons, located in perifornical hypothalamus (de lecea et al., 1998; Sakurai et al., 1998), influence appetite, the sleep-wake cycle, locomotor activity as well as a number of physiological variables. Transgenic mice with ataxin3-mediated destruction of orexin neurons have attenuated...

  • Parkinson's disease: When to take the car keys. DiLoreto, Stacy // Patient Care;Apr2002, Vol. 36 Issue 6, p77 

    Presents the results of a study which evaluated several patients with Parkinson's disease. Excessive daytime sleepiness found in patients; Significance of the use of Epworth Sleepiness Scale and the Inappropriate Sleep Composite Score questionnaire; Recommendation on screening patients with...

  • Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study. Romigi, A.; Stanzione, P.; Marciani, M. G.; Izzi, F.; Placidi, F.; Cervellino, A.; Giacomini, P.; Brusa, L.; Grossi, K.; Pierantozzi, M. // Journal of Neural Transmission;Dec2006, Vol. 113 Issue 12, p1909 

    Few studies focused on the effects of cabergoline on sleep-wake cycle in PD. Twelve patients affected by PD treated with levodopa as monotherapy underwent two 24-hour ambulatory polysomnographic (A-PSG) sessions twice: in baseline condition (levodopa as monotherapy) and after addition of...

  • Good practice in the assessment and management of nocturnal Parkinson's disease symptoms. Medcalf, Pippa // Age & Ageing;Sep2005, Vol. 34 Issue 5, p435 

    Discusses the assessment and management of nocturnal Parkinson's disease (PD) symptoms. Results of a survey of sleep-related symptoms experienced by PD patients in Great Britain; Disease-related and treatment-related factors affecting the sleep and wake continuum in such patients; Treatment...

  • Orexins and Gastrointestinal Functions. Baccari, M. C. // Current Protein & Peptide Science;Mar2010, Vol. 11 Issue 2, p148 

    Orexin A (OXA) and orexin B (OXB) are recently discovered neuropeptides that appear to play a role in various distinct functions such as arousal and the sleep-wake cycle as well as on appetite and regulation of feeding and energy homeostasis. Orexins were first described as neuropeptides...

  • Relaciones entre el sueño y la adicción. CAñELLAS, FRANCESCA; DE LECEA, LUIS // Adicciones;2012, Vol. 24 Issue 4, p287 

    While it is well known that there is an interaction between sleep disorders and substance abuse, it is certainly more complex than was previously thought. There is a positive relationship both between having a substance use disorder and suffering from a sleep disorder, and vice versa. The...

  • Studies Shine Light, Literally, On Neural Substrates Of Sleep. Breindl, Anette // BioWorld Today;10/18/2007, Vol. 18 Issue 203, p1 

    The article discusses a research about the neural substrates of sleep, which appeared in the October 18, 2007 issue of the journal "Nature" and in the October 2007 issue of "PLoS Biology." An examination of the function of neurotransmitter hypocretin revealed its involvement during the...

  • Sleep disorders: Counting orexins. Wiedemann, Claudia // Nature Reviews Drug Discovery;Mar2007, Vol. 6 Issue 3, p187 

    The article focuses on the role of antagonist of orexin receptors in the sleep-wake cycle. A study by Jenck and colleagues is discussed that examines the use of orexin receptor antagonist that elicits somnolence without cataplexy when administered at single doses during the active period of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics